Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Though outcomes for pediatric Burkitt lymphoma (BL) have improved significantly in recent decades with intensive multi-agent chemotherapy and the addition of rituximab, chemotherapy resistance remains a significant impediment to cure following relapse. Activation of the PI3K/AKT pathway has been imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatti, Maria, Ippolito, Thomas, Mavis, Cory, Gu, Juan, Cairo, Mitchell S., Lim, Megan S., Hernandez-Ilizaliturri, Francisco, Barth, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955151/
https://www.ncbi.nlm.nih.gov/pubmed/29774105
http://dx.doi.org/10.18632/oncotarget.25072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955151/
https://www.ncbi.nlm.nih.gov/pubmed/29774105
http://dx.doi.org/10.18632/oncotarget.25072

Ejemplares similares